BVNRY:OTCMKTS
Bavarian Nordic A/S - ADR
၁၁.၇၈ US$
arrow_downward
-၁.၅၄%(-၀.၁၈) 1D
အောက် ၁၃, GMT-၄ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BVNRY...
Open
၁၁.၇၇ US$
High
၁၁.၇၈ US$
Low
၁၁.၇၇ US$
Mkt. cap
၂၈၀.၁၇ ဋေ
Avg. vol.
၃.၀၄ ထောင်
Volume
၈၉၅.၀၀
P/E ratio
၁၂.၇၀
52-wk high
၁၃.၀၀ US$
52-wk low
၈.၆၇ US$
EPS
၀.၉၃ US$
Beta
၁.၄၅
Shares outstanding
၂၃.၇၈ ကုဋေ
No. of employees
၂ ထောင်
Open
၁၁.၇၇ US$
High
၁၁.၇၈ US$
Low
၁၁.၇၇ US$
Mkt. cap
၂၈၀.၁၇ ဋေ
Avg. vol.
၃.၀၄ ထောင်
Volume
၈၉၅.၀၀
P/E ratio
၁၂.၇၀
52-wk high
၁၃.၀၀ US$
52-wk low
၈.၆၇ US$
EPS
၀.၉၃ US$
Beta
၁.၄၅
Shares outstanding
၂၃.၇၈ ကုဋေ
No. of employees
၂ ထောင်
News stories
From web sources and news partners
PR Newswire UK
·
ပြီးခဲ့သည့် ၃၆ မိနစ်
Oracle NetSuite Announces Launch of AI-first QuickStart: NYSE Content Update
GlobeNewswire
·
ပြီးခဲ့သည့် ၁ နာရီ
Delixy Holdings Limited Regains Compliance with Nasdaq Minimum Bid Price Requirement
Yahoo Finance
·
ပြီးခဲ့သည့် ၅၆ မိနစ်
33-Year History Shows How to Profit Even When a Market Crash Hits
Reuters
·
ပြီးခဲ့သည့် ၅၁ မိနစ်
SNAPSHOT S&P 500 futures turn negative after Sept inflation data
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S - ADR